The benefits of statin therapy have been repeatedly underestimated, and the harms exaggerated, due to misinterpretation of the evidence, according to authors of a major review of the evidence published in The Lancet.
With over 30 years of research, generating a large amount of data from a wide variety of patients, statins have been proven to lower cholesterol by 2 mmol/L preventing major cardiovascular events in 1.5 out of every ten patients, while potentially causing adverse events such as myopathy, haemorrhagic strokes or diabetes in 1% to 2% of patients.
The irreversibility and "devastating" nature of heart attacks, make the benefits of statin therapy far outweigh the risks, without even referencing other secondary benefits, authors said.
CLICK HERE for The Lancet article.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Sep 16
